Added to YB: 2025-10-28
Pitch date: 2025-10-25
NVO [bullish]
Novo Nordisk A/S
-5.27%
current return
Author Info
HatedMoats identifies hated moats. I buy companies when the market panics. Contrarian investor focused on quality, value & long-term growth. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 339.00
Price Target
99.00 (-69%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
Novo Nordisk (NVO): DCF Valuation
NVO: DCF yields DKK 637 ($99) price target vs DKK 360 current, 44% margin of safety. 70% obesity market share, 44.2% EBIT margin, 63.9% ROIC. Base case: 10.2% 10yr revenue CAGR to DKK 750B by 2034, margins compress to 40%. Bear case DKK 318 only 12% below current price, bull DKK 1,150. Market pricing bear case as likely outcome.
Read full article (6 min)